DNA-encoded chemical library

North America Leads the Way in the Global DNA Encoded Library Market, Capturing Over 70% of Market Share by 2035 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 23, 2023
Research, Technology, Neurology, Genetics, Biotechnology, Pharmaceutical, Health, Science, Oncology, Artificial Intelligence, Bristol Myers Squibb, AstraZeneca, Patent, Region, Janssen, Intellectual property, Jaden Philogene, Intellectual, DNA, Drug development, Artificial intelligence, Wuxi, Novartis, Machine learning, DNA-encoded chemical library, DEL, GenScript Biotech, Amgen, Drug discovery, GSK, Chem, DSM-IV codes, Services marketing, USD, Roche, Sanofi, Library, Therapy, Fine chemical, Pharmaceutical industry, Medical device, Computer data storage, Pfizer, Florence Provendier, Dels

With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.

Key Points: 
  • With robust innovation and substantial financial support from investors, the DNA encoded library market is poised for remarkable expansion.
  • Market Analysis and Regional Dominance:
    The global DNA encoded library market is estimated to reach USD 840 million in 2023.
  • North America is expected to hold the largest market share, with more than 70% of the market captured by players based in North America and Europe by 2035.
  • Leading DNA Encoded Library Companies:
    Key players in the DNA encoded library market include BOC Sciences, DyNAbind, Edelris, GenScript, HitGen, NovAliX, PROVendis, SpiroChem, Vipergen, WuXi AppTec, and X-Chem.

The opportunity within the DNA Encoded Library Market to grow at 16% CAGR till 2035, according to a market research report by Roots Analysis

Retrieved on: 
Tuesday, September 5, 2023
Chem, DNA, Partnership, Table, DNA-encoded chemical library, Intelligence, Research, USD, Acquisition, Machine learning, Drug discovery, Artificial intelligence, Growth, Library, Computer data storage, Fine chemical, Dynamo

LONDON, Sept. 5, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "DNA Encoded Library Market, 2023-2035" report to its list of offerings.

Key Points: 
  • Owing to its access to the largest chemical space available in the market, DNA encoded chemical library platforms are a natural fit for big data analytics and modeling technologies offered by artificial intelligence and machine learning.
  • Insitro made the acquisition to leverage Haystack Sciences DNA sequencing technology to enhance its machine learning based drug discovery capability.
  • Additionally, Google Research also collaborated with X-Chem in 2020 to develop an effective method for finding biologically active molecules using physical and virtual screening.
  • Further, in 2021, Relay Therapeutics acquired ZebiAI for USD 85 million upfront, allowing them to incorporate the machine learning based DNA encoded chemical library technology into their protein targeting platform, Dynamo.

The opportunity within the DNA Encoded Library Market to grow at 16% CAGR till 2035, according to a market research report by Roots Analysis

Retrieved on: 
Tuesday, September 5, 2023
Chem, DNA, Partnership, Table, DNA-encoded chemical library, Intelligence, Research, USD, Acquisition, Machine learning, Drug discovery, Artificial intelligence, Growth, Library, Computer data storage, Fine chemical, Dynamo

LONDON, Sept. 5, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "DNA Encoded Library Market, 2023-2035" report to its list of offerings.

Key Points: 
  • Owing to its access to the largest chemical space available in the market, DNA encoded chemical library platforms are a natural fit for big data analytics and modeling technologies offered by artificial intelligence and machine learning.
  • Insitro made the acquisition to leverage Haystack Sciences DNA sequencing technology to enhance its machine learning based drug discovery capability.
  • Additionally, Google Research also collaborated with X-Chem in 2020 to develop an effective method for finding biologically active molecules using physical and virtual screening.
  • Further, in 2021, Relay Therapeutics acquired ZebiAI for USD 85 million upfront, allowing them to incorporate the machine learning based DNA encoded chemical library technology into their protein targeting platform, Dynamo.

Philogen Announces Publication of a New Study in Collaboration with Google focused on Machine Learning models applied to DNA-Encoded Chemical Library Technology

Retrieved on: 
Tuesday, March 28, 2023
Tissue, Antigen, Intellectual property, DNA, Chemical library, Renal cell carcinoma, Dels, Ligand, Research, HIT, Blood, Protein, CAIX, Machine learning, DEL, Carbonic anhydrase, Drug discovery, Artificial intelligence, Neoplasm, Hypoxia, DNA-encoded chemical library, Vaccine, Pharmaceutical industry, Jaden Philogene

Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).

Key Points: 
  • Siena, Italy, March 28, 2023 - Philogen S.p.A., a clinical-stage biotechnology company focused on the development of innovative antibody and small molecule ligands, announces the publication of a new study conducted in collaboration with Google focused on the use of Machine Learning models applied to the screening of DNA-Encoded Chemical Libraries (DELs).
  • The technology allows the rapid selection of specific binders (“Phenotype”), physically connected to unique DNA tags (“Genotype”) that work as amplifiable identification barcodes.
  • Philochem has synthesized several DNA-Encoded Chemical Libraries, featuring different designs, that have yielded high affinity and selective binders to a variety of target proteins of pharmaceutical interest.
  • These ligands - human monoclonal antibodies or small organic molecules - are identified using Antibody Phage Display Libraries and DNA-Encoded Chemical Library technologies.

Board of Directors Approves Half-Year Financial Report as of June 30, 2022

Retrieved on: 
Wednesday, September 28, 2022
Financial statement, IFRS, Phase, Jaden Philogene-Bidace, Contract, Company, Treasury, Genta (company), Compliance, Doxorubicin, Intellectual property, Legislature, Melanoma, Industry, Business, Glioblastoma, Book, Program, Patient, Clinical trial, Investment, Cancer, Ligand, AIFA, Finance, Blood, Share repurchase, Report, Antigen, Board of directors, Tissue, Method, Press release, Board, Lomustine, Research, Marketing, Business development, HIV disease progression rates, GMP, DNA-encoded chemical library, Disease, Mission statement, Renewable energy, Pharmaceutical industry, Medical imaging, Vaccine, Audit, Group, Montarioso

In the same period, liquidity increased from 92,593 thousand as of March 31, 2022 to 98,339 thousand as of June 30, 2022, showing an increase of approximately 6.2%.

Key Points: 
  • In the same period, liquidity increased from 92,593 thousand as of March 31, 2022 to 98,339 thousand as of June 30, 2022, showing an increase of approximately 6.2%.
  • Current and non-current financial debt decreased from 16,248 thousand as of March 31, 2022, to 16,225 thousand as of June 30, 2022, showing a decrease of approximately 0.14% resulting from the progress of existing amortization schedules.
  • Opening of new centers in Germany, Spain, Italy and Poland for the European Phase III study of first-line soft tissue sarcoma.
  • The Board of Directors approved the Group Sustainability Brochure, referring to the year 2021, which will be published on the Company's website ( https://www.philogen.com) in the "Governance" section.

Versant Ventures Launches Vector BioPharma AG

Retrieved on: 
Wednesday, August 10, 2022
Health, Health Technology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Fraunhofer Society, Â, Program management, Gene, CEO, Technology, Investment, Protein engineering, Board, GE Healthcare, Tissue, Patient, Roche, DNA, Therapy, DNA-encoded chemical library, Epitope, Biotechnology, Safety, Epilepsy, Novartis, CRISPR Therapeutics, Neuroscience, Head, Business operations, Venture, Initial public offering, University, AstraZeneca, Immune system, AAV, Fine chemical, Vaccine, Pharmaceutical industry, Antibiotics, Management, Versant, Bayer, Vector

Versant Ventures today announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform that is devoid of viral genes.

Key Points: 
  • Versant Ventures today announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform that is devoid of viral genes.
  • Versant has made several important investments in genetic medicine, including founding Crispr Therapeutics, and we believe that Vector represents a new wave of innovation in this space, said Markus Enzelberger, Ph.D., Partner at Versant and a Vector board member.
  • Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients.
  • Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies.

Animol Discovery, Inc. Announces Series B Financing of $34.0 million to Advance Its Pipeline of Novel Veterinary Pharmaceuticals

Retrieved on: 
Thursday, July 28, 2022
Health, Consumer, Agriculture, Natural Resources, Pets, Pharmaceutical, Veterinary, DNA, Algorithm, Time, DNA-encoded chemical library, Thermo Fisher Scientific, Livestock, Bayer, Crop protection, Boehringer Ingelheim, Industry, Farmer, Human, Doctor of Philosophy, Novalis, DEL, CEO, Drug discovery, Relay, Probability, Board, List of life sciences, Marijn Dekkers, Veterinary medicine, Quality of life, Machine learning, Director, Technology, Board of directors, Â, DVM, Animal, Pharmaceutical industry, Management, Fine chemical

Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing.

Key Points: 
  • Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing.
  • The proceeds allow the company to expand and advance its pipeline of novel active pharmaceutical ingredients through clinical development and further enhance its cutting-edge drug discovery platform.
  • The $40Bn animal health industry continues to demand novel medicines to treat infectious and chronic diseases in companion and production animals.
  • Pet parents and livestock farmers continue to demand novel veterinary pharmaceuticals that can protect animals against diseases and improve quality of life, said Andrew Plant PhD, chief executive officer, Animol Discovery.

Philogen Provides Corporate Update

Retrieved on: 
Wednesday, September 29, 2021
Melanoma, Nominal interest rate, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, TNF, Population, L19, FAP, DNA-encoded chemical library, Contract research organization, Food and Drug Administration, AIFA, GMP, Squamous cell carcinoma, Food, National academy, European Medicines Agency, CEO, Group, Teaching hospital, Disease, Ligand, Soft-tissue sarcoma, Dacarbazine, Clinical trial, Neoplasm, Therapy, Cancer, Gallium, Nuclear medicine, Marketing, Company, Heterotrimeric G protein, Medicine, Tissue, Data, Intellectual property, Department, Lomustine, Patient, IL2, PSA, IDH, Antigen, Research, Blood, Pharmaceutical industry, Fine chemical, Vaccine, Medical imaging, Medical device

Clinical experience with OncoFAP confirms preclinical results, recently published in Proceedings of the National Academy of Sciences U.S.A.

Key Points: 
  • Clinical experience with OncoFAP confirms preclinical results, recently published in Proceedings of the National Academy of Sciences U.S.A.
    Siena (Italy), 29 September 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody- and small molecule-based targeted therapeutics announces its Interim Results for the six month period ended 30th June 2021 and provides an update regarding recent corporate developments.
  • Nidlegy is a pharmaceutical product, proprietary to Philogen, consisting of two active ingredients, L19-IL2 and L19-TNF.
  • Additional countries are planned to be involved in Phase II studies;
    Fibromun is a pharmaceutical product, proprietary to Philogen, consisting of the L19 antibody fused to TNF.
  • OncoFAP is a small organic molecule, proprietary to Philogen group, with affinity for Fibroblast Activation Protein (FAP).

Global Pharmaceutical Contract Research Services Market (2021 to 2030) - by Scale of Operation, Target Therapeutic Areas and Key Geographies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Professional Services, Health, Legal, Clinical Trials, Research, Science, Pharmaceutical, Diversified Pharmaceutical Services, DEL, Partnership, Center for Drug Evaluation and Research, Research, Review, USD, DNA-encoded chemical library, FDA, Ownership, Acquisition, Knowledge, Center, Cros, Drug development, Drug discovery, Investment, US, Industry, Tetanic contraction, Pharmaceutical industry, Fine chemical, Risk management

Moreover, drug discovery and clinical research are capital intensive processes, which, on average, require investments in the range of USD 4-10 billion.

Key Points: 
  • Moreover, drug discovery and clinical research are capital intensive processes, which, on average, require investments in the range of USD 4-10 billion.
  • What is the total cost of ownership required to set up a pharmaceutical contract research organization?
  • A region-wise, detailed analysis of the total cost of ownership for a pharmaceutical contract research service provider.
  • A case study on the current market landscape of biopharmaceutical contract research service providers, including information on the year of establishment, company size, scale of operation and type of services offered.

Available Now! Whitepaper: Advancing Drug Discovery Through DNA Encoded Library Technology!

Retrieved on: 
Friday, May 28, 2021
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Life sciences, Biotechnology, Health sciences, Pharmaceutical sciences, Pharmaceutics, Nucleic acids, Molecular biology, DNA, Helices, Drug discovery, DNA-encoded chemical library

HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today.

Key Points: 
  • HitGen and Fierce Biotech jointly release the Whitepaper: Advancing Drug Discovery through DNA-Encoded Library (DEL) Technology today.
  • As demonstrated above, DEL potentials in drug discovery and/or other areas are being gradually explored.
  • DEL screening methods and models are being developed to include covalent screening, protein degradation molecular screening, and cell model-based DEL screening.
  • To explore more about technologies and services about HitGens DNA encoded library, please contact [email protected] .